Synfacts 2022; 18(09): 1027
DOI: 10.1055/s-0041-1738566
Innovative Drug Discovery and Development

A Tunicamycin Analogue Inhibits Human Phosphotransferase, DPAGT1

Contributor(s):
Dirk Trauner
,
Tufan K. Mukhopadhyay
Mitachi K, Mingle D, Effah W, Sánchez-Ruiz A, Hevener KE, Narayanan R, Clemons WM. Jr, Sarabia F, Kurosu M. * University of Tennessee Health Science Center, Memphis, USA
Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor.

Angew. Chem. Int. Ed. 2022;
61: e202203225
 

Significance

The naturally occurring nucleoside antibiotics, tunicamycins are of potential synthetic interest due to their nonselective cytotoxic and cytostatic activities. The authors report a 15-step synthesis of a tunicamycin analogue, TN-TMPA, which shows selective cytostatic activity against breast cancer cell lines. When compared to the natural analogue TN-V,TN-TMPA shows 12.5 times higher inhibition of dolichyl-phosphate N-acetylglucosamine-phosphotransferase (DPAGT1) – a protein responsible for abnormal N-linked glycosylation in cancer cells.


#

Comment

The molecule contains a disaccharide fragment and a uridine fragment. The key reaction in the synthesis is a Büchner–Curtius–Schlotterbeck-type reaction to couple the disaccharide with the uridine moiety. This reaction occurs via a diazoalkane intermediate. Deprotonation and nucleophilic addition to aldehyde following a 1,2-hydride shift afford the ketone product. Finally, a highly stereoselective Meerwein–Pondorf–Verley reduction and N-acylation yields TN-V or TN-TMPA.


#
#

Publication History

Article published online:
18 August 2022

© 2022. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany